Related Experiment Video
Updated: Jan 28, 2026

Historical View and Physiology Demonstration at the NMJ of the Crayfish Opener Muscle
Published on: November 9, 2009
What lurks in the shadows of the openness hyperbole for biopharmaceuticals?
1Centre for Advanced Studies in Bio-Medical Innovation Law (CeBIL), University of Copenhagen, Copenhagen S, Denmark.
Abstract:
Recent advances in transparency initiative signify laudable developments. Yet, a closer look on the legal developments indicates that commercially confidential information and personal data will continue to pose persisting challenges for clinical trial transparency and drug development. This article depicts these developments with a particular focus on European Medicines Agency (EMA) and Biologics. We argue that in order to promote the development of innovative biologics and biosimilars, the EMA will need to carefully consider and address such challenges.
Related Concept Videos
Hyperbolic and Inverse Hyperbolic Functions: Problem Solving
Hyperbolic Functions
Biopharmaceutics and Pharmacokinetics: Overview
Spanning Openings in Brick Walls
Lintels are primary supports used to span openings and can be crafted from materials such as reinforced concrete, steel-reinforced brick masonry, or simple steel angles. These are straightforward to install and are typically concealed...
Inverse Hyperbolic Functions and Their Derivatives
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

